Mannkind reported $4.5 million in revenue for the fourth quarter and $11.75 million for the full year, significantly increasing product sales revenue while it transitions away from its former collaboration with Sanofi. Shares fell more than 5 percent to $2.78 as of noon on Feb. 28 after the company announced another stock offering, raising $50…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
